FASANO, MASSIMO
 Distribuzione geografica
Continente #
NA - Nord America 1690
EU - Europa 1645
AS - Asia 1464
Continente sconosciuto - Info sul continente non disponibili 21
SA - Sud America 11
OC - Oceania 3
AF - Africa 2
Totale 4836
Nazione #
US - Stati Uniti d'America 1684
CN - Cina 956
UA - Ucraina 709
SE - Svezia 392
FR - Francia 203
IN - India 190
TR - Turchia 178
FI - Finlandia 163
VN - Vietnam 118
IT - Italia 68
DE - Germania 38
GB - Regno Unito 38
EU - Europa 21
AT - Austria 9
BE - Belgio 7
SY - Repubblica araba siriana 7
UY - Uruguay 7
PK - Pakistan 6
RU - Federazione Russa 6
CA - Canada 4
BG - Bulgaria 3
ES - Italia 3
AR - Argentina 2
AU - Australia 2
CH - Svizzera 2
IE - Irlanda 2
IR - Iran 2
KR - Corea 2
MX - Messico 2
NL - Olanda 2
SA - Arabia Saudita 2
CL - Cile 1
GH - Ghana 1
IQ - Iraq 1
ML - Mali 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PE - Perù 1
TH - Thailandia 1
Totale 4836
Città #
Jacksonville 505
Dearborn 317
Nanjing 281
Chandler 219
Nyköping 211
Wilmington 137
Dong Ket 117
Nanchang 102
Princeton 102
Beijing 101
San Mateo 79
Helsinki 69
Shenyang 60
Hebei 52
Kunming 51
Tianjin 44
Ann Arbor 35
Changsha 34
Jiaxing 34
Ningbo 29
Jinan 26
Stevenage 24
Des Moines 23
Zhengzhou 21
Hilden 19
Hangzhou 17
Guangzhou 15
Lanzhou 15
Taizhou 13
Redwood City 12
Vienna 9
Woodbridge 9
Ankara 8
Chengdu 8
Foggia 8
Shanghai 8
Montevideo 7
Orange 7
Hefei 6
Norwalk 6
Boardman 5
Brussels 5
Changchun 5
Augusta 4
Fairfield 4
Leawood 4
Zhangzhou 4
Borås 3
Fuzhou 3
Istanbul 3
Jinhua 3
New York 3
Rockville 3
Saint Petersburg 3
Bari 2
Elche 2
Hanover 2
Kraainem 2
Modena 2
Oxford 2
Paris 2
Pennington 2
Perm 2
Pesaro 2
Priverno 2
Redmond 2
Rome 2
Acquaviva Delle Fonti 1
Ashburn 1
Balıkesir 1
Baotou 1
Bethesda 1
Brindisi 1
Brooklyn 1
Cedar Knolls 1
Chongqing 1
Christchurch 1
Dammam 1
Edinburgh 1
Edmonton 1
Federal 1
Florence 1
Gaziantep 1
Geneva 1
Gijón 1
Haikou 1
Hanoi 1
Huai Khwang 1
Hyderabad 1
Kuala Lumpur 1
Lima 1
London 1
Mendoza 1
Mountain View 1
Philadelphia 1
Phoenix 1
Qingdao 1
Reggio Nell'emilia 1
Seoul 1
Shaoxing 1
Totale 2951
Nome #
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 127
2-years effectiveness and safety of tenofovir in 302 NUC-naïve patients with chronic hepatitis B: a multicenter European study in clinical practice 106
2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE 85
5-year Entecavir in NUC-naïve, field practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC 83
Four years of tenofovir monotherapy for NUC naive field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 73
Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study 73
An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C. 70
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 68
EFFICACY AND SAFETY OF LONG-TERM THERAPY WITH ENTECAVIR (ETV) OR TENOFOVIR (TDF) IN PATIENTS WITH HBV-RELATED CIRRHOSIS 68
Flares during long-term entecavir therapy in chronic hepatitis B 68
5-YEAR ENTECAVIR TREATMENT IN NUC-NAIVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS 64
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: a multicenter real-life study in 103 patients 64
THE ITALIAN ENTAS COHORT STUDY: ENTECAVIR EFFECTIVENESS IN NAïVE AND TREATMENT EXPERIENCED PATIENTS WITH CHRONIC HEPATITIS B 63
Nucleios(t)ide analogue discontinuation is not associated with increased rates of HBsAg loss in chronic hepatitis B 63
Efficacia e tollerabilità della monoterapia con Entecavir (ETV) in pazienti con epatite cronica B 62
ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT 61
Tenofovir suppressed viral suppression in most field practice, treatment-naive patients with CHB followed for 3 years in a multicenter European study 60
Nuove strategie di trattamento 60
preliminary Data From the Study of Coagulative Profile of HIV infected Individuals suggest a role for point mutations in the Gene in protein S deficiency in Individuals undergoing Higly Antiretroviral therapy 59
Resistance profile of entecavir in patients with chronic hepatitis B 57
Acute Hepatitis C in Haemodialysis patients: natural course and response to IFNα-monotherapy 56
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 55
Analisi di costo-efficacia del trattamento dell’epatite cronica B con analoghi nucleos(t)idici nella pratica clinica 55
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 55
Risposta virologica e resistenza ad Adefovir dipivoxil (ADV) in pazienti con Epatite Cronica B resistente alla Lamivudina (LAM) 55
Risposta alla terapia con Adefovir Dipivoxil (ADV) in pazienti con Epatite Cronica B, resistenti alla Lamivudina 55
Acute hepatitis C: clinical and laboratory diagnosis, course of the disease, treatment. 55
Patients with HDV infection and advanced fibrosis/cirrhosis present a high but predictable risk of developing hepatocellular carcinoma 55
Long-term response to lamivudine monotherapy in patients with HBeAg-negative chronic hepatitis B: to change or not to change? 54
Effectiveness of entecavir for NUC-naïve, HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 54
HBsAg loss is enough to discontinue long-term nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B patients in real practice 54
.Long-term lamivudine treatment in patients with HBeAg negative chronic hepatitis B: how long? 53
Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin 52
Current Concepts on Management of Chronic Hepatitis BPractical Management of Chronic Viral Hepatitis 52
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-interferon α-2b versus a 12 week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with acute hepatitis C 52
ENTECAVIR EFFECT ON LIVER FUNCTION IN FIELD PRACTICE: INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 51
Tenofovir monotherapy suppressed viral suppression in most field practice, treatment-naive patients with chronic hepatitis B followed for 3 years in a multicenter European study 51
Interim analysis of the Italian Master-Entas cohort study: entecavir effectiveness in field practice for chronic hepatitis B 51
Epatite acuta C in un’ampia coorte di pazienti: fattori di rischio ed evoluzione 51
Epatite acuta C a risoluzione spontanea: evoluzione a lungo termine 51
Long-term follow up of patients with acute hepatitis C and spontaneous resolution 50
Mutations selected during lamivudine therapy may predispose to adefovir resistance 50
A proposito di epatite B. News da EASL 2008. 50
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin 50
PREDICTION OF HBeAg SEROCONVERSION IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS TREATED WITH ENTECAVIR USING ALT AND PLATELET COUNT: RESULTS FROM A LARGE EUROPEAN MULTI-CENTER STUDY 50
Risk of hepatocellular carcinoma in chronic hepatitis B patients treated with nucleos(t)ide analogues and long-term virological suppression 50
Chronic hepatitis B: Advances in treatment. 50
Entecavir treatment for NUC naïve, field practice patients with chronic hepatitis B: excellent viral suppression and safety profile over 5 years of treatment 48
Adefovir resistance patterns in patients with lamivudine resistant chronic hepatitis B 48
Epatite B e Immigrazione 48
A MODEL TO PREDICT SUCCESS FOLLOWING PEG-INTERFERON AND RIBAVIRIN THERAPY FOR PATIENTS WITH HCV-1 INFECTION 48
No beneficial of long-term analogue treatment on the clinical outcome of patients with chronic hepatitis Delta and advanced liver disease. A case-control study. 48
Detection of in vivo hepatitis B virus surface antigen mutations-a comparison of four routine screening assays 47
Selection of HCV-1 patients with chronic hepatitis who might benefit from current standard of therapy with peg-interferon and ribavirin. 19th International Symposium on Hepatitis C Virus and Related Viruses 46
Early hepatic flares during ETV treatment are rare and do not require treatment adaptation in chronic hepatitis B without cirrhosis 46
Long-Term HDV-RNA Suppression – HBsAg Clearance in Chronic Hepatitis D Following Interferon Therapy 46
Cost-effectiveness of Tenofovir in the treatment of patients with chronic hepatitis B: data from literature 46
Malattie causate da Elminti 46
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B 46
Effectiveness of entecavir in field practice: interim analysis of the Italian MASTER-ENTAS cohort study of patients with chronic hepatitis B 45
Definizione delle resistenze e metodiche di laboratorio 45
Come trattare il paziente con non risposta o risposta virologica parziale 45
Longitudinal PAGE-B Scores Predict the Risk of Hepatocellular Carcinoma and other Adverse Clinical Outcomes in Chronic Hepatitis B Patients on Entecavir Therapy 45
Maintained viral suppression and excellent safety profile of Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B: a 4-year field practice, multicenter study 44
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 44
Diagnostic value of alpha-fetoprotein for early hepatocellular carcinoma diagnosis in cirrhotic HBV patient successfully treated with nucleos(t)ide analogues - a case report 44
Tenofovir monotherapy for naïve patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months 43
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 43
Impact of adding raltegravir to antiretroviral regimens in patients with blood viral suppression but persistent seminal viral shedding 43
Studio multicentrico, randomizzato per valutare l’efficacia e la sicurezza di un ciclo di monoterapia con Peg-Interferone alfa-2b della durata di 24 settimane verso un trattamento di 12 settimane di Peg-interferone alfa-2b in monoterapia o in associazione alla ribavirina in pazienti con epatite acuta C 43
HBV and immigrants: a SIMIT multicenter cross-sectional study 42
Efficacia e tollerabilità a lungo termine della monoterapia con entecavir in pazienti con Epatite Cronica B 42
Epatite acuta C in pazienti in trattamento emodialitico periodico. 42
Genotypic resistance to adefovir (ADV) in patients with lamivudine (LAM) resistant chronic hepatitis B 42
Reply. 41
Entecavir for NUC-naïve chronic hepatitis B patients in clinical practice: long-term effectiveness from large multicenter cohort study in 376 patients 41
Dalla terapia di combinazione Lamivudina+Adefovir alla monoterapia con Tenofovir in pazienti con Epatite Cronica B, HBeAg-negativa: risultati di efficacia e sicurezza 41
Risposta a lungo termine alla monoterapia con lamivudina in pazienti con epatite cronica B, HBeAg negativa: è opportuno cambiare? 41
HBV e migranti: risultati di uno studio multicentrico SIMIT 41
HBSAG LOSS IS ENOUGH TO DISCONTINUE LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN REAL PRACTICE? 41
Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B 41
Terapia a lungo termine con Lamivudina in pazienti con epatite cronica B anti-HBe positiva: quando sospendere? 41
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis 40
Effectiveness and safety of therapy simplification from Lamivudine + Adefovir to Tenofovir monotherapy in virologically suppressed HBeAg-negative chronic hepatitis B patients 40
Interim analysis of the Italian Master-Entas cohort study: entecavir can improve liver function in patients with chronic hepatitis B and liver cirrhosis 40
Entecavir monotherapy in 418 NUC-naïve patients with chronic hepatitis B from field practice: high efficacy and favourable safety profile over 3 years of treatment 40
HCV genotype 1 subtypes (1a and 1b): similarities and differences in clinical features and therapeutic outcome 40
Lack of association between IL28B variants and HBsAg clearance after interferon treatment 39
Effectiveness of entecavir for nuc-naive HBeAg-negative chronic hepatitis B patients in clinical practice: a 2-year multicenter cohort study in 311 patients 39
ENTECAVIR EFFECTIVENESS IN DAILY CLINICAL PRACTICE, INTERIM ANALYSIS OF THE ITALIAN Master-Entas COHORT STUDY OF PATIENTS WITH CHRONIC HEPATITIS B 39
ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS 39
An open, randomized, multicentre trial to evaluate efficacy and safety of a 24 week-course of Peg-Interferon α-2b versus a 12-week-course of Peg-Interferon α-2b alone or plus ribavirin in patients with Acute Hepatitis C 37
Epatiti virali croniche e gravidanza 37
Entecavir in “real-life”: risultati dello studio VIRGIL 37
Prediction of hepatocellular carcinoma in entecavir treated patients: results from 744 chronic hepatitis B patients in European Multicenter Study (VIRGIL) 35
Effectiveness and safety of tenofovir disoproxil fumarate in field practice: a multicenter European cohort study of 302 NUC-naïve patients with chronic hepatitis B 35
Efficacia e sicurezza della terapia a lungo termine con Entecavir (ETV) o Tenofovir (TDF) in pazienti con cirrosi epatica HBV correlata 35
La genetica dei virus epatitici: implicazioni cliniche e terapeutiche 34
Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. 34
Il caso clinico: monoterapia o terapia di combinazione?. 32
Totale 5066
Categoria #
all - tutte 12967
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12967


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201832 0000 00 012 11243
2018/2019712 36576 163105 1807 71416148
2019/20201532 3531408118 201205 21218 1302613315
2020/2021917 12721058 1099 12121 11911828150
2021/2022554 74879 7332 1554 666816132
2022/2023656 237915876 53138 21 0000
Totale 5109